NCT06828393招募中1 期
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Trial of S-1117 in Healthy Volunteers
Seismic Therapeutic AU Pty Ltd1 个研究点 分布在 1 个国家目标入组 96 人开始时间: 2025年3月最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 96
- 试验地点
- 1
- 主要终点
- Number of participants with treatment-related adverse and serious adverse events as assessed by CTCAE v5.0
研究概览
简要总结
This is the first-in-human study of S-1117 designed to provide safety, tolerability, pharmacokinetic, and pharmacodynamic data in healthy volunteers.
详细描述
This is a randomized, placebo-controlled, double-blind, study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of S-1117 administered to healthy adult participants. This study will be conducted in two parts, Part 1 (single ascending dose, SAD) and Part 2 (multiple ascending doses, MAD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Is available for the entire duration of the study and follow up.
- •Is willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
- •Voluntarily consents to participation in the trial as documented by signing the study informed consent form (ICF).
- •Has a body mass index (BMI) within 18 to 32 kg/m2, inclusive, and weighs ≥45 kg.
- •Is in good physical and mental health in the opinion of the Investigator or delegate.
排除标准
- •Has a history of severe allergic or anaphylactic reaction as determined by the Investigator or delegate.
- •Is pregnant, nursing, or is planning to become pregnant or breastfeed during the trial.
- •Has a known immunodeficiency disorder.
- •Has a history of malignancy other than non-melanoma skin cancer.
- •Has a history of human immunodeficiency virus (HIV) or positive serology for HIV at Screening.
- •Has positive laboratory evidence for active hepatitis at screening.
- •Has received a live vaccine within 2 months of Screening.
- •Has any other condition or prior therapy that, in the opinion of the Investigator or delegate, may potentially compromise the safety or compliance of the participant, or may preclude the participant from successfully completing the study.
- •Other inclusion/exclusion eligibility criteria apply.
研究组 & 干预措施
S-1117 Part 1: Single ascending dose (SAD) cohorts
Experimental
干预措施: S-1117 (Drug)
S-1117 Part 1: Single ascending dose (SAD) cohorts
Experimental
干预措施: Placebo (Other)
S-1117 Part 2: Multiple ascending dose (MAD) cohorts
Experimental
干预措施: S-1117 (Drug)
S-1117 Part 2: Multiple ascending dose (MAD) cohorts
Experimental
干预措施: Placebo (Other)
结局指标
主要结局
Number of participants with treatment-related adverse and serious adverse events as assessed by CTCAE v5.0
时间窗: 2 months
次要结局
- To assess the maximum serum concentration (CMAX)(2 months)
- To assess time to reach maximum serum concentration (tMAX)(2 months)
- To assess elimination half-life (t1/2)(2 months)
- To assess area under the serum concentration-time curve from time 0 to t hours (AUC0-t) and to infinity (AUC0-inf)(2 months)
- To assess clearance (CL)(2 months)
- To assess volume of distribution (Vz) and steady-state volume of distribution (Vss)(2 months)
- To assess bioavailability after SC administration (F%)(2 months)
- To characterize absolute and proportional change from baseline of immunoglobulin G (IgG) at multiple timepoints(2 months)
- Incidence and characterization of antidrug antibody (ADA)(2 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy ParticipantsAlzheimers10012303Alzheimer's DiseaseNL-OMON51440Denali Therapeutics Inc.80
已完成
1 期
Study of ZYN002 (cannabidiol gel) in 40 Healthy VolunteersMental Health - Other mental health disordersNeurological - EpilepsyMusculoskeletal - OsteoarthritisHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersEpilepsyFragile X SyndromeOsteoarthritisACTRN12618000183280Zynerba Pharmaceuticals Pty. Ltd.40
已完成
1 期
A first in human study assessing the safety and pharmacokinetics (blood levels) of RA101495.ACTRN12615001143516Clinical Network Services Pty Ltd40
已完成
1 期
A first in Human single-Center Study To Evaluate the effectiveness and Safety Of A Live Attenuated Dengue Vaccine (KD-382) In Healthy AdultsInfection - Other infectious diseasesInflammatory and Immune System - Normal development and function of the immune systemDengue FeverACTRN12618001027202KM Biologics Co., Ltd.60
已完成
不适用
A Phase I, Randomized, Placebo-controlled, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen® (Poly I:Poly C12U) in Healthy SubjectsCoronaCOVID-19SARS-CoV-210047438NL-OMON50834AIM ImmunoTech Inc.40